2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P10799
    SLAFVDVLN 98%
    SLAFVDVLN, a molecular peptide, is a BACE-1 inhibitor with a Ki value of 94 nM. SLAFVDVLN can reduce Aβ42 production.
    SLAFVDVLN
  • HY-P10811
    Na2+ - Ca2+ Exchanger inhibitory peptide 98%
    Na+-Ca2+ Exchanger inhibitory peptide (XIP) is a Na+-Ca2+ exchanger inhibitor with a Ki of 200 nM. Na+-Ca2+ Exchanger inhibitory peptide inhibits the Na+-dependent Ca2+ uptake and the Na+-dependent Ca2+ efflux of sarcolemmal vesicles in a noncompetitive manner.
    Na2+ - Ca2+ Exchanger inhibitory peptide
  • HY-P10818
    Polyglutamine binding peptide 1 274914-75-9 98%
    Polyglutamine binding peptide 1 (QBP1) is a peptide inhibitor of polyglutamine (polyQ). Polyglutamine binding peptide 1 inhibits polyQ protein aggregation in vitro and suppresses polyQ-induced cell death in cell culture.
    Polyglutamine binding peptide 1
  • HY-P10822
    ED11 1593480-56-8 98%
    ED11 is a potent and selective caspase-6 inhibitor with an IC50 of 12.12 nM. ED11 competes with Htt for the caspase-6 active site, and thus reduce Htt cleavage. ED11 can cross the blood-brain barrier (BBB). ED11 has the potential for the study of Huntington's disease (HD).
    ED11
  • HY-P10823
    RI-OR2 1219627-58-3 98%
    RI-OR2, a retro-inverso peptide, is an amyloid-β (Aβ) oligomerization inhibitor. RI-OR2 binds to immobilized β-Amyloid (1-42) (HY-P1363A) monomers and fibrils, with an apparent Kd of 9-12 μM, and also acted as an inhibitor of Aβ(1-42) fibril extension.
    RI-OR2
  • HY-P10824
    RI-OR2-TAT 1430219-69-4 98%
    RI-OR2-TAT is a brain-penetrant inhibitor of β-Amyloid oligomerization, which is produced by adding the HIV protein transduction domain TAT to RI-OR2. RI-OR2-TAT binds to Aβ42 fibrils with a Kd value of 58-125 nM. RI-OR2-TAT reduces Aβ aggregation and plaque levels, reduces activation of microglia and oxidative damage, and increases the number of young neurons in the dentate gyrus.
    RI-OR2-TAT
  • HY-P1083A
    Dynamin inhibitory peptide TFA 98%
    Dynamin inhibitory peptide TFA competitively blocks binding of dynamin to amphiphysin, thus preventing endocytosis. Dynamin inhibitory peptide TFA blocks the dopamine D3 effect on GABAA receptors.
    Dynamin inhibitory peptide TFA
  • HY-P1084A
    β-Pompilidotoxin TFA 98%
    β-Pompilidotoxin TFA (β-PMTX TFA), a wasp venom, can slow sodium channel inactivation and increases steady-state sodium current in cells.
    β-Pompilidotoxin TFA
  • HY-P10854
    TAT-N15 2415370-74-8 98%
    TAT-N15 is a p55PIK inhibitor with remarkable anti-inflammatory activity and neuroprotective effects. TAT-N15 can significantly inhibit the activation of IL-6, IL-8, Akt, and NF-κB pathways, as well as suppress the protein expression of phosphorylated STAT3 and NF-κB. By inhibiting the activation of Akt, STAT3, and NF-κB pathways, TAT-N15 is used in research on acute conjunctivitis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and stroke.
    TAT-N15
  • HY-P10861
    RI-AG03 98%
    RI-AG03 is an orally active and a BBB-penetrable Tau aggregation peptide inhibitor. RI-AG03 inhibits Tau aggregation and improves associated neurodegeneration and behavioral phenotypes in both in vivo and in vitro models. RI-AG03 can be used in the study of tauopathies such as Alzheimer's disease.
    RI-AG03
  • HY-P10876
    mcK6A1 98%
    mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases.
    mcK6A1
  • HY-P10898
    GeX-2 2900996-95-2 98%
    GeX-2 is a truncated analogue of αO-conotoxin. GeX-2 activates GABAB receptor. GeX-2 inhibits α9α10 nAChR and CaV2.2 channels. GeX-2 alleviates pain in the rat model of chronic constriction injury.
    GeX-2
  • HY-P1090A
    Hemopressin(rat) TFA 1431329-47-3 98%
    Hemopressin(rat) TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) TFA exerts antinociceptive action in inflammatory pain models.
    Hemopressin(rat) TFA
  • HY-P1091A
    Hemopressin(human, mouse) TFA 1431329-48-4 98%
    Hemopressin TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin TFA exerts antinociceptive action in inflammatory pain models.
    Hemopressin(human, mouse) TFA
  • HY-P10928
    BCY17901 TFA 98%
    BCY17901 TFA is a potent irreversible transferrin receptor 1 (TfR1) inhibitor (Ki=12 nM). BCY17901 TFA inhibits TfR1-mediated endocytosis and iron transport, suppressing the proliferation of tumor cells dependent on iron metabolism. BCY17901 TFA is promising for research of solid tumors, such as breast cancer, glioblastoma and neurodegenerative diseases.
    BCY17901 TFA
  • HY-P10932
    pGk13a 98%
    pGk13a is an azide (azide group can be combined with fluorophore)-containing amphiphilic membrane labeling probe. pGk13a enables high-resolution imaging of cell membranes in the ultrastructural membrane expansion microscopy (umExM) technique, facilitating the observation of membrane-associated structures and proteins. pGk13a can be used for neuronal structural studies.
    pGk13a
  • HY-P10936
    AQP4 (201-220) 2104700-59-4 98%
    AQP4 (201-220) is an encephalitogenic epitope of AQP-4. AQP4 (201-220) can induce experimental autoimmune encephalomyelitis (EAE) (characterized by midline lesions in the brain, retinal pathology, and lesions at the grey matter/white matter border zone in the spinal cord). AQP-4 is a target antigen in neuromyelitis optica.
    AQP4 (201-220)
  • HY-P10942
    CGN peptide 2421211-40-5 98%
    CGN peptide is a 13 amino acid peptide composed of D-amino acids, referred to as CGN peptide. CGN peptide is the retro-inverso isomer of the l-peptide TGN (TGNYKALHPHNG) and can deliver siRNA to the blood-brain barrier (BBB). CGN peptide can be used in Alzheimer's disease (AD) research.
    CGN peptide
  • HY-P10962
    Rugecitide 2938226-27-6 98%
    Rugecitide is a neuregulin 4 (NRG4) analog.
    Rugecitide
  • HY-P1112A
    Sarafotoxin S6a TFA 98%
    Sarafotoxin S6a TFA , a sarafotoxin analogue, is a endothelin receptor agonist and has an ETA/ETB selectivity profile similar to that of Endothelin-3 (HY-P0204). Sarafotoxin S6a TFA elicits the pig coronary artery with an EC50 value of 7.5 nM.
    Sarafotoxin S6a TFA
Cat. No. Product Name / Synonyms Application Reactivity